lundi 14 octobre 2019

Onco Actu du 14 octobre 2019


1. BIOLOGIE



An ambitious effort to map the human body’s individual cells gets backing from NIH - An ambitious effort to map the human body’s individual cells gets backing from NIH [Science]











2.7 ETIOLOGIE - OBÉSITÉ



Overweight before age 40 increases the cancer risk [University of Bergen]










3.1.1 PRÉVENTION - TABAC - E-CIGS



Scientists chase cause of mysterious vaping illness as death toll rises [Nature]










Vaping-related illness has a new name: EVALI [STAT]











No Drop in Vaping Cases, C.D.C. Says [NY Times]











U.S. health officials say vaping illness may have multiple causes [Reuters]











4.15 DÉP., DIAG. & PRONO. - IMAGERIE



Imaging tumour stiffness could help enhance treatment for breast and pancreatic cancer [Institute of Cancer Research]











5.17 TRAITEMENTS - RADIOTHÉRAPIE



Taking RTKI drugs during radiotherapy may not aid survival, worsens side effects [Penn State]











5.2 PHARMA



Seattle Genetics Announces Initiation of Phase 3 Clinical Trial of Tucatinib in Combination with Ado-trastuzumab Emtansine (T-DM1, Kadcyla®) for Patients with Advanced or Metastatic HER2-Positive Breast Cancer [Seattle Genetics]











5.2.3 PHARMA - ÉCONOMIE



PhRMA’s talking points shouldn’t derail the Pelosi drug pricing bill [STAT]











5.4 TRAITEMENTS - ECONOMIE



Clovis' Rubraca, trailing PARP rivals, nabs England coverage thanks to NICE U-turn [Fierce Pharma]










Clovis Oncology Announces Rubraca®▼ (Rucaparib) Now Available For Women With Relapsed Ovarian Cancer In England Through The Cancer Drugs Fund [Clovis Oncology]











In reversal, NICE backs Rubraca after Clovis agrees to a price cut [EndPoints]











6.1 OBSERVATION



Men account for a small fraction of breast cancer cases. Their fatality rate has soared compared with women’s [STAT]











Womb cancer stats reveal treatment variation across England [Cancer Research UK]